ClinicalTrials.gg
Active, not recruitingNCT06449027Updated Oct 1, 2025

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

A Phase 3 interventional study of T Leuprolide Injectable Emulsion and Leuprorelin Acetate Microspheres for Injection in Breast Cancer Subjects, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 133 studies testing tamoxifen in Breast Neoplasms — 16 open to participants now, 30 under way, 9 of them phase 3. Tamoxifen · Breast Neoplasms.

Enrollment
56th of 126
211 · median 169
Started
2024
with 2 others
Phase 3
57 of 133
4 open now
Primary completion
2025-11
later than 12 of 29 live
Registered
128th of 133
by date

Among the 133 studies testing tamoxifen in Breast Neoplasms, this one is the 56th largest by enrollment of the 126 interventional ones that give a count, is one of 3 that started in 2024, is one of 57 in phase 3, reaches primary completion later than 12 of the 29 other live ones, and was the 128th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 133 studies testing tamoxifen in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies testing tamoxifen in Breast Neoplasms, or all of them as a file.
02

Study summary

The study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Read the detailed description

This is a multicenter, randomized, open-Label , non-inferiority phase III study . All premenopausal women breast cancer subjects were randomly allocated to either the study group or control group in a 1:1 ratio. Furthermore, all subjects received tamoxifen citrate treatment throughout the entire duration of the study. The efficacy of maintaining serum E2 levels ≤30 pg/mL at 4-48 weeks post-treatment will be assessed in both groups.

03

Conditions studied

  • Breast Cancer Subjects

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal female subjects aged 18 to 55 years old.
  • Histological or cytological confirmation of HR+,- premenopausal breast cancer.
  • Subjects have any breast cancer surgery before informing, and no clinical residual local regional lesions were found after the surgery.
  • is not less than 12 weeks.
  • (ECOG) performance status of 0 or 1.
  • Adequate function of major organs.

Exclusion criteria

Exclusion Criteria:

  • History of evidence of distant lesions;
  • Subjects have the history of new or adjuvant endocrine treatment for breast cancer ( Excluding subjects receiving tamoxifen citrate tablets treatment for less than 12 weeks before informing).
  • Active , or in screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Leuprolide Injectable Emulsion

    100 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks.

    Drug: T Leuprolide Injectable Emulsion

  • Active comparator
    Leuprorelin Acetate Microspheres for Injection

    100 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks.

    Drug: Leuprorelin Acetate Microspheres for Injection

Interventions

  • Arm 1 subjects were injected Leuprolide Injectable Emulsion 42mg every 24 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.

    Also known as: Tamoxifen Citrate Tablets

  • Arm 2 subjects were injected Leuprorelin Acetate Microspheres for Injection 11.25mg every 12 weeks for 48 weeks, and taked Tamoxifen Citrate Tablets 10mg bid for 48 weeks.

    Also known as: Tamoxifen Citrate Tablets

06

What researchers measure

Primary outcomes

  1. Observe the proportion of subjects whose E2 levels remain at postmenopausal levels between 4 and 48 weeks after treatment, to assess the Efficacy of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subject.

    Time frame: 48 weeks

Secondary outcomes

  1. Observe the concentration of LH, FSH, E2 after treatment.

    Time frame: 48 weeks

  2. Pharmacokinetic Parameter(AUC)

    Time frame: 48 weeks

  3. Pharmacokinetic Parameter(Cmax)

    Time frame: 48 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2025, 15 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 15 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 7, 2024
StartActual
Aug 21, 2024
Primary completionEst.
Nov 2025
CompletionEst.
Mar 2026
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06449027
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Aug 21, 2024
Primary completion
Nov 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Oct 1, 2025

Study contacts

Jian Zhang, Doctor
principal investigator · Fudan University
Zhimin Shao, Doctor
principal investigator · Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion